Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 2/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6484310 | 0.98 | APP (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL936436 | 0.98 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Iodide SCHEMBL9693917 | 0.98 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL5249711 | 0.96 | APP (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL9466518 | 0.96 | APP (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL9814518 | 0.79 | CYP2C9 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Iodide SCHEMBL18110427 | 0.79 | HRH1 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL1739222 | 0.78 | HIF1A (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Bromide SCHEMBL10446668 | 0.77 | MAPK14 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Bromide SCHEMBL15635739 | 0.77 | HIF1A (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | ALLERGAN, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3156387-B1 | METHOD OF PREPARING INDENE DERIVATIVES | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-07-25 | — | — | EP | disclosed |
| EP-3277704-A1 | CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS | ALLERGAN, INC. (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3156387-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2017-04-19 | — | — | EP | disclosed |
| WO-2016160362-A1 | CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS | ALLERGAN, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | ALLERGAN, INC. | 2016-10-06 | — | — | US | disclosed |
| EP-2277848-B1 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-09-14 | — | — | EP | disclosed |
| US-20150307426-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2015-10-29 | — | — | US | disclosed |
| US-20140371252-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0318860-A2 | Substituted alkylamine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-06-07 | — | — | EP | disclosed |
| US-4826833-A | ANTIBIOTICS | PFIZER INC. (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0239874-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-07 | — | — | EP | disclosed |
| EP-0150433-B1 | PROCESS FOR THE PREPARATION OF INSATURATED KETONES | BASF Aktiengesellschaft (DE) | 1986-12-30 | — | — | EP | disclosed |
| EP-0150433-A2 | Process for the preparation of insaturated ketones | BASF Aktiengesellschaft (DE) | 1985-08-07 | — | — | EP | disclosed |
| EP-0150984-A2 | 6-(Substituted) methylenepenicillanic and 6-(substituted) hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1985-08-07 | — | — | EP | disclosed |
| EP-0049776-B1 | 4-QUINOLINE METHANE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF SUBSTANCES WITH A PHARMACOLOGICAL ACTIVITY | BASF Aktiengesellschaft (DE) | 1985-07-31 | — | — | EP | disclosed |
| US-4429130-A | Pyrid-2'-yl-2-trifluoromethyl quinol-4-ylmethanes | BASF AKTIENGESELLSCHAFT (DE) | 1984-01-31 | — | — | US | disclosed |
| EP-0049776-A2 | 4-Quinoline methane derivatives, their preparation and their use in the preparation of substances with a pharmacological activity | BASF Aktiengesellschaft (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307426-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSRR, INSR, IDO1 | GRIN2D 4228/4885GRIN3B 3593/4885GRIN1 3342/4885 |
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | CHP1, UACA, CRYAB | GRIN2D 4751/4885GRIN3B 3507/4885GRIN1 4442/4885 |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | CHP1, UACA, CRYAB | GRIN2D 4751/4885GRIN3B 3507/4885GRIN1 4442/4885 |
| US-20140371252-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSRR, INSR, IDO1 | GRIN2D 4228/4885GRIN3B 3593/4885GRIN1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.